122 related articles for article (PubMed ID: 1468695)
1. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Untch M; Sevin BU; Perras JP; Angioli R; Baibl A; Nguyen HN; Hightower RD; Averette HE
Gynecol Oncol; 1992 Nov; 47(2):172-8. PubMed ID: 1468695
[TBL] [Abstract][Full Text] [Related]
2. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
[TBL] [Abstract][Full Text] [Related]
3. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
5. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Hightower RD; Sevin BU; Perras JP; Untch M; Angioli R; Ramos R; Averette H
Gynecol Oncol; 1992 Nov; 47(2):186-90. PubMed ID: 1468696
[TBL] [Abstract][Full Text] [Related]
6. The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Nguyen HN; Sevin BU; Averette HE; Perras J; Donato D; Penalver M
Gynecol Oncol; 1992 May; 45(2):185-91. PubMed ID: 1592285
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Hightower RD; Sevin BU; Perras J; Nguyen H; Angioli R; Untch M; Averette H
Cancer Invest; 1993; 11(3):276-82. PubMed ID: 8485650
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.
Kurbacher CM; Mallmann P; Kurbacher JA; Sass G; Andreotti PE; Rahmun A; Hübner H; Krebs D
Anticancer Res; 1994; 14(5A):1961-5. PubMed ID: 7847834
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines.
Nguyen HN; Sevin BU; Averette H; Perras J; Untch M; Ramos R; Donato D; Penalver M
Gynecol Oncol; 1992 May; 45(2):164-73. PubMed ID: 1592283
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
12. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
13. [An evaluation of adenosine triphosphate bioluminescence assay for tumor in vitro chemosensitivity testing].
Liu S; Peng Z; Lou J; Wang H; Tang Q; He B
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):330-3. PubMed ID: 12545824
[TBL] [Abstract][Full Text] [Related]
14. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
16. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
18. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
19. [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect].
Takamizawa H; Sekiya S; Iwasawa H; Ishige H; Tokita H; Tanaka N
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2293-7. PubMed ID: 2416274
[TBL] [Abstract][Full Text] [Related]
20. [Result of individualized chemotherapy with a newly developed in vitro chemosensitivity testing in ovarian cancer].
Iijima N; Sekiya S; Tokita H; Oosaki T; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Oct; 43(10):1323-8. PubMed ID: 1955784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
